Italy Backs New Deep-Tech Therapeutics Fund With €20 Million Public Commitment

Italy is putting more venture capital behind science before it becomes a company

Italy is expanding one of the most difficult parts of its innovation system: financing scientific technologies before they become mature businesses.

BII Catalyst Fund I for Italy has been created to support early-stage therapeutics companies emerging from Italian universities, laboratories and research teams, with the Lazio region serving as an initial geographic anchor.

The fund completed a first close above €20 million in July and is backed by a €20 million commitment from Lazio Innova through LAZIO Venture 2, the regional fund-of-funds co-financed through the European Regional Development Fund programme.

Novo Holdings, the investment company owned by the Novo Nordisk Foundation, is participating alongside the public investor.

Panakès Partners, a Milan-based venture-capital manager specialising in life sciences, manages the vehicle.

The BioInnovation Institute in Copenhagen will help identify and develop scientific projects before they reach conventional institutional venture financing.

The structure reflects a broader change taking place across European technology investment.

Governments increasingly recognize that producing excellent scientific research is not enough.

Researchers also need capital, business-building support, laboratories, regulatory expertise and investors willing to finance years of development before meaningful revenue appears.

The €20 million number requires an important distinction

The new vehicle is sometimes described as a €20 million fund.

That is not quite accurate.

The fund's first close was above €20 million.

The exact €20 million figure refers to Lazio Innova's cornerstone commitment through LAZIO Venture 2.

Novo Holdings is also an investor, meaning the total fund size at first close exceeds the Lazio contribution.

That distinction matters because the public commitment is being used as a foundation for a broader public-private investment structure rather than representing the entire pool of capital.

The strategy is designed to bring institutional and specialist private investors alongside regional and European public resources.

The fund operates at the earliest stages of company creation

BII Catalyst Fund I for Italy is not designed primarily for mature biotechnology companies preparing large clinical trials or commercial launches.

Its mandate begins much earlier.

Lazio Innova lists eligible investment stages as pre-incorporation, pre-seed and seed.

Individual investments can range from €500,000 to €4 million.

That means the fund can potentially become involved before a scientific project has even been formally incorporated into a standalone company.

This stage is particularly important in biotechnology.

Many promising technologies originate inside universities or research institutes where the scientific work may be strong but the entrepreneurial structure is still incomplete.

Researchers may have intellectual property but no chief executive.

They may have laboratory validation but no regulatory development plan.

They may know that a biological mechanism works but not yet have the financing required to turn the discovery into a clinical product.

Conventional venture investors can consider such projects too early or too technically uncertain.

The new fund is designed specifically around that gap.

Therapeutics are the central focus

Despite the broader deep-tech description, BII Catalyst Fund I for Italy is not a general fund for robotics, semiconductors, space or industrial AI.

Its investment policy is focused on human-health biotechnology.

Lazio Innova says the fund can invest in therapeutic drug development, including biologics, small molecules and cell therapies.

It can also finance therapeutic medical technologies, diagnostics and prognostics.

The mandate extends to enabling technologies that support those fields.

That includes artificial-intelligence and quantum-computing applications for drug discovery.

This matters because the boundary between biotechnology and computing is becoming increasingly blurred.

Modern drug discovery increasingly relies on machine learning, computational chemistry, structural biology and large-scale biological datasets.

A company can therefore be both a life-science company and a deep-tech software or computing company at the same time.

The real target is the gap between academic discovery and investable startup

Europe produces large volumes of scientific research but has repeatedly struggled to convert enough of that work into large technology companies.

Life sciences provide one of the clearest examples.

A university laboratory may discover a promising therapeutic target.

The research team then needs to validate the underlying biology.

Intellectual property has to be protected.

A company may need to be created around the technology.

Preclinical studies must be designed.

Manufacturing questions begin to appear.

Regulatory strategy becomes necessary.

Experienced executives need to join the project.

All of that happens before the company can reach the stages normally associated with large venture rounds.

BII Catalyst Fund I is designed to finance and support this transition.

BioInnovation Institute adds more than money

The BioInnovation Institute is an important part of the model because the fund is not intended to operate solely as a financial vehicle.

BII has developed programmes that help researchers and founders build companies around scientific technologies.

Panakès says BII has supported more than 140 startups since its creation.

Its programmes provide infrastructure, expertise, networks and financing to life-science and deep-tech companies.

For the Italian fund, BII is expected to help identify promising scientific teams and provide access to its innovation platform.

That means a potential portfolio company can receive assistance before it becomes ready for a conventional Series A financing round.

Panakès provides the specialist investment layer

Panakès Partners will manage the investment fund.

The Milan-based venture-capital firm was founded in 2015 and focuses on life-science technologies.

It reports approximately €250 million under management.

Specialist fund management matters in therapeutics because investment decisions require more than ordinary financial analysis.

Investors have to evaluate biological mechanisms, intellectual property, clinical development pathways, manufacturing complexity, regulatory strategy and competitive science.

A promising laboratory result can still fail during preclinical or clinical development.

That technical uncertainty is one reason life-science venture capital tends to require specialised investment teams.

Novo Holdings brings a global life-science investor into the structure

Novo Holdings' participation adds another layer of institutional experience.

The Danish investment company manages the assets of the Novo Nordisk Foundation and is the controlling shareholder of Novo Nordisk and Novonesis.

It is also a major international life-science investor.

Its involvement gives the Italian vehicle a connection to a wider European biotechnology investment ecosystem.

For early-stage Italian founders, those international networks may eventually be as valuable as the initial capital.

A successful therapeutic company generally requires multiple financing rounds and may eventually need investors from several countries.

A €1 million or €3 million seed cheque can start the company.

It cannot finance an entire drug-development programme.

The fund therefore needs to prepare companies for larger pools of capital later.

Lazio is using public money to crowd private investors into high-risk technology

BII Catalyst Fund I sits inside the much larger LAZIO Venture 2 strategy.

Lazio Innova currently lists approximately €100.33 million for the programme.

Instead of investing all that money directly into startups itself, Lazio Venture 2 commits capital to professionally managed investment funds.

Those funds then evaluate and invest in startups under their own investment processes.

The policy particularly targets areas where normal private markets may provide insufficient capital, including deep tech, hard tech, technology transfer and strategic technologies covered by Europe's STEP framework.

This fund-of-funds structure attempts to combine public capital with professional venture selection rather than requiring regional officials to pick individual biotechnology companies.

Six co-financed venture funds are now part of the Lazio programme

Lazio Innova says the selection process attracted 15 proposals representing about €260 million of requested commitments.

The programme ultimately financed five dedicated funds and one parallel fund.

The vehicles became operational from August 2026.

BII Catalyst Fund I is one of them.

Other funds cover areas ranging from dual-use technology and defence to artificial intelligence, spacetech, quantum computing, cybersecurity and broader biotechnology.

The result is much larger than a single €20 million commitment.

Lazio is attempting to create a regional network of specialised venture funds capable of supporting companies at different stages and in different technology categories.

BII Catalyst can invest between €500,000 and €4 million

The ticket range provides useful insight into the strategy.

At €500,000, a fund can support company formation, proof-of-concept work or early technical validation.

At the upper end, a €4 million investment can finance a more substantial seed programme and help a young biotechnology company reach a meaningful development milestone.

In therapeutics, those milestones matter enormously.

The valuation of a company can change substantially when a programme moves from an academic hypothesis to validated preclinical evidence.

Later investors often want evidence that specific technical risks have already been reduced.

An early-stage specialist fund can therefore create value by financing the expensive work required to remove those risks.

The fund can invest before incorporation

Pre-incorporation investment is one of the more unusual elements.

It allows the investment process to begin when the underlying opportunity still exists mainly as intellectual property, researchers and experimental results.

This resembles a venture-creation model rather than ordinary startup investing.

A fund may help assemble management, structure the intellectual property licence, establish the company and design the first commercial development plan.

That model is particularly relevant in European universities, where high-quality science may exist without a founding team that already has experience building a venture-backed company.

Italy is trying to improve technology transfer nationally

The new Lazio vehicle is part of a wider Italian push to turn scientific research into companies.

On September 22, CDP Venture Capital launched SophIA, a national technology-transfer hub focused on artificial intelligence and cybersecurity.

SophIA starts with €27.5 million allocated from CDP Venture Capital's Technology Transfer Fund and Artificial Intelligence Fund.

It aims to support more than 20 initiatives across proof-of-concept, pre-seed and seed stages during the next three years.

Its scientific partners include the University of Naples Federico II, Politecnico di Milano, the Italian Institute of Artificial Intelligence, Fondazione Bruno Kessler and the Italian Institute of Technology.

The technological scope includes foundation models, intelligent agents, robotics, digital twins, edge computing, neuromorphic hardware, AI accelerators and high-performance computing.

That initiative demonstrates that Italy's early-stage deep-tech strategy now extends well beyond life sciences.

Larger technology-transfer funds are emerging too

Italy is also attracting larger pools of specialist capital.

Poli360 2, managed by 360 Capital, reached an €85 million close earlier in 2026 and is continuing fundraising toward a €100 million target.

The fund plans roughly 20 to 25 early-stage deep-tech investments and is built around relationships with Italian universities and research centres.

At least 80% of its investment focus is expected to remain in Italy, with up to 20% available for European opportunities.

The European Investment Fund is meanwhile acting as a cornerstone investor in Obloo Future of Computing Fund I.

Obloo is targeting approximately €80 million and plans to invest primarily in Italy across artificial intelligence, quantum computing, semiconductor technology, microelectronics, cybersecurity, industrial technology and AI-driven drug discovery.

These vehicles indicate that Italian technology-transfer capital is beginning to become more specialised.

Deep tech needs a different financing model from conventional software

A software startup can sometimes build a product using a small engineering team and reach customers within months.

A therapeutic startup can spend years generating evidence before it has anything commercially saleable.

A semiconductor company may need expensive hardware development.

A quantum startup may require specialized laboratory equipment.

A robotics company has to build and test physical systems.

These businesses frequently need patient capital because technical development occurs before predictable revenue.

That creates a financing problem.

Traditional bank loans are poorly suited to companies with few physical assets and no stable cash flow.

Generalist venture funds may prefer businesses that can validate markets more quickly.

Deep-tech funds are designed around longer development cycles and much higher scientific risk.

Public capital can absorb part of the early uncertainty

This is one reason governments increasingly intervene at the earliest stages.

Public funding can help a technology cross the period when commercial investors are least willing to participate.

If the technology succeeds, private capital can enter later once technical risk has declined.

The objective is not for government money to finance a company permanently.

It is to move projects far enough that normal venture markets can take over.

BII Catalyst explicitly describes this as bridging the gap between scientific discovery and later-stage investment readiness.

The model still depends on private-market discipline

Government involvement also creates risks.

Publicly backed investment can become ineffective if capital is distributed primarily according to political priorities rather than technical and commercial merit.

The Lazio programme attempts to limit that problem by allocating capital through independently managed venture funds.

The investment managers remain responsible for assessing companies and deciding which projects receive money.

Lazio Innova says managers evaluate proposals autonomously according to their own investment criteria and decision-making processes.

That separation is important if the programme is to produce commercially viable companies rather than simply subsidised research projects.

Biotechnology is well suited to the Lazio region

The geographic focus also reflects existing industrial strengths.

Lazio, centred around Rome, has a significant pharmaceutical and life-science ecosystem, research institutions, hospitals, universities and multinational companies.

That gives new therapeutics companies potential access to experienced scientific workers, clinical partners and industry expertise.

The regional strategy aims not only to support companies already located in Lazio but also to attract businesses willing to establish and develop operational activities there.

Venture capital therefore becomes part of regional economic-development policy.

Successful startups could create a multiplier effect

A strong life-science startup can generate value far beyond the founding team.

It hires scientists.

It uses specialist laboratories.

It contracts with manufacturers.

It works with hospitals and clinical researchers.

It hires regulatory consultants, lawyers and intellectual-property specialists.

If it raises larger international rounds, foreign capital flows into the local ecosystem.

And if successful founders eventually create or invest in other companies, the local venture ecosystem becomes more self-sustaining.

This is the long-term logic behind technology-transfer funds.

The goal is not merely to finance research.

It is to turn research into companies capable of attracting more capital and creating industrial activity.

The hardest test comes after the first seed investment

Launching a fund is much easier than producing successful therapeutics companies.

Drug development has extremely high failure rates.

Scientific results may not reproduce outside the original laboratory.

Preclinical studies can reveal safety problems.

Clinical trials can fail to show sufficient efficacy.

Regulatory requirements can increase costs.

Companies may struggle to manufacture complex products consistently.

And capital requirements rise rapidly as programmes progress.

For BII Catalyst, success will therefore depend on more than deploying its initial money.

Its portfolio companies will need to reach technical milestones strong enough to attract later investors.

The first meaningful metric will be follow-on capital

An early-stage technology-transfer fund should eventually be judged by what happens after its initial investment.

How many university projects become companies?

How many companies raise institutional seed or Series A rounds?

How much international capital enters the ecosystem?

How many therapeutic programmes advance toward clinical development?

How much intellectual property remains connected to Italian companies and research institutions?

Those outcomes will provide a more meaningful measure than the initial fund size alone.

Italy's deep-tech financing architecture is becoming more layered

BII Catalyst Fund I now occupies one particular point in a larger financing system.

It targets early therapeutics.

SophIA targets early AI and cybersecurity technologies.

Poli360 2 targets a broader portfolio of early-stage deep tech.

Obloo is being built around future computing technologies.

European programmes such as the EIC can provide additional financing as companies mature.

This layering is important because a single generic venture fund cannot realistically provide the specialized technical knowledge required across biotechnology, semiconductors, robotics and quantum computing.

The €20 million commitment is therefore more significant than its size suggests

Compared with global technology funds measured in billions, €20 million can appear modest.

But the capital is being deployed at a stage where individual projects may initially require hundreds of thousands rather than hundreds of millions.

With investment tickets beginning at €500,000, the fund can support multiple scientific programmes before they have matured into traditional venture-backed startups.

The strategic objective is leverage.

A relatively small amount of early capital helps create a company.

That company reaches a technical milestone.

A larger venture investor enters.

Clinical or industrial partners follow.

If enough projects move through that sequence, €20 million of cornerstone capital can ultimately support a much larger amount of private investment.

Italy is betting that more of its science can become companies

The underlying policy problem is familiar across Europe.

Strong universities generate valuable discoveries.

Too few discoveries become globally significant technology companies.

BII Catalyst Fund I for Italy is one attempt to intervene at the point where that process often breaks down.

It places specialist venture capital closer to scientists.

It provides investment before or shortly after company formation.

It connects Italian research to an international biotechnology network.

And it combines regional public capital with professional private investment management.

The vehicle's first close above €20 million is only the beginning.

The real measure of success will be whether technologies currently sitting in Italian laboratories become drugs, diagnostics and medical technologies capable of attracting global capital and reaching patients.

If that happens, Italy will not simply be financing more startups.

It will be capturing more economic value from the scientific research it already produces.